DexCom Inc (BSP:D1EX34)
R$ 9.65 0 (0%) Market Cap: 188.46 Bil Enterprise Value: 189.05 Bil PE Ratio: 47.26 PB Ratio: 15.58 GF Score: 74/100

Dexcom Inc at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 05:45PM GMT
Release Date Price: R$11.99
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Thanks, everyone. If you can take a seat, we can start the next session here. I am Robbie Marcus, the med tech analyst at JPMorgan. Very happy to introduce Kevin Sayer, the CEO of DexCom. Kevin is going to do a presentation and then me and Jereme will join him on stage for some Q&A after.

Kevin Ronald Sayer
DexCom, Inc. - Executive Chairman, CEO & President

Thank you, Robbie. You know those who work with me often say I start our meetings by asking a very simple question, what problem are we trying to solve today? Well, diabetes is a big problem. With the estimated global population of people with diabetes growing from 150 million in the year 2000 to more than 500 million in year 2021 and approaching just under 800 million in the year 2045. This is a problem that's just not going away. And most of these people are still treated by fingersticks.

And it's not just the growth in the population that's staggering, it's the cost associated with their care. It costs the system

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot